The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here: https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

Imaging androgen receptor signaling with a radiotracer targeting free prostate-specific antigen.

På svenska

Author

  • David Ulmert
  • Michael J Evans
  • Jason P Holland
  • Samuel L Rice
  • John Wongvipat
  • Kim Pettersson
  • Per-Anders Abrahamsson
  • Peter T Scardino
  • Steven M Larson
  • Hans Lilja
  • Jason S Lewis
  • Charles L Sawyers
Show all

Summary, in English

Despite intense efforts to develop radiotracers to detect cancers or monitor treatment response, few are widely used as a result of challenges with demonstrating clear clinical use. We reasoned that a radiotracer targeting a validated clinical biomarker could more clearly assess the advantages of imaging cancer. The virtues and shortcomings of measuring secreted prostate-specific antigen (PSA), an androgen receptor (AR) target gene, in patients with prostate cancer are well documented, making it a logical candidate for assessing whether a radiotracer can reveal new (and useful) information beyond that conferred by serum PSA. Therefore, we developed (89)Zr-labeled 5A10, a novel radiotracer that targets "free" PSA. (89)Zr-5A10 localizes in an AR-dependent manner in vivo to models of castration-resistant prostate cancer, a disease state in which serum PSA may not reflect clinical outcomes. Finally, we demonstrate that (89)Zr-5A10 can detect osseous prostate cancer lesions, a context where bone scans fail to discriminate malignant and nonmalignant signals.

Publishing year

2012

Language

English

Pages

320-327

Publication/Series

Cancer Discovery

Volume

2

Issue

4

Document type

Journal article

Publisher

American Association for Cancer Research

Topic

  • Cancer and Oncology

Status

Published

Research group

  • Clinical Chemistry, Malmö
  • Urological cancer, Malmö
  • Urological research, Malmö

ISBN/ISSN/Other

  • ISSN: 2159-8274